Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer
Clinical trial NCT07302841 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07302841
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-20
- Primary completion
- 2027-06-20
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.